Japan PM Ishiba to announce resignation by August end – Mainichi
FREMONT, Calif. - Personalis, Inc. (NASDAQ: PSNL), a precision oncology company with a market capitalization of $433 million and impressive revenue growth of 15.6% over the last twelve months, has reported that its NeXT Personal circulating tumor DNA (ctDNA) blood test can detect cervical cancer progression up to 16 months earlier than imaging methods. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 6.91, positioning it well for continued research and development. The findings, stemming from the phase 3 CALLA study, were presented at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago and simultaneously published in the Annals of Oncology.
The study analyzed blood samples from 186 patients with locally advanced cervical cancer using the NeXT Personal test post-chemoradiotherapy (CRT). Results showed that ctDNA levels were a strong predictor of cervical cancer progression risk. Patients with undetectable ctDNA levels approximately three months after completing CRT had at least a 95% lower risk of progression and death. Conversely, the presence of ctDNA after CRT indicated a higher risk of disease progression, detectable a median of about five months and up to about 16 months before it could be seen on imaging scans. The market has responded positively to Personalis’s innovations, with the stock delivering a remarkable 233% return over the past year.
Personalis’ Chief Medical Officer, Dr. Richard Chen, emphasized the significance of these results for the management of cervical cancer, which is the fourth most common cancer in women worldwide. The company, which specializes in advanced genomics for precision oncology, views the NeXT Personal test as a potential tool for guiding treatment decisions and personalizing patient care in high-risk cervical cancer cases.
The press release also highlighted the company’s broader mission to transform cancer management through personalized testing. Personalis’ assays are designed to detect minimal residual disease (MRD) and recurrence at early stages, aid in selecting targeted therapies, and enhance biomarker strategies for drug development.
This news is based on a press release statement and has not been independently verified. It should be noted that forward-looking statements involve risks and uncertainties, and actual results may differ materially from those anticipated. Personalis has cautioned against placing undue reliance on these forward-looking statements, which are valid only as of the date of the press release. For deeper insights into Personalis’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which offer expert analysis of over 1,400 US stocks.
In other recent news, Personalis reported first-quarter 2025 earnings that exceeded analyst expectations, with an earnings per share (EPS) of -$0.18 compared to the forecasted -$0.25. The company also surpassed revenue predictions, posting $20.6 million against an expected $17.5 million. Personalis experienced a notable 39% year-over-year increase in its biopharma revenue, driven by the growth in its NeXT Personal molecular tests and the launch of the NextPersonal MRD test. Additionally, H.C. Wainwright maintained a Buy rating on Personalis and raised the price target from $8.00 to $9.00, reflecting confidence in the company’s growth trajectory. The firm also extended its financial projections to 2032, predicting significant revenue growth for Personalis. The company’s focus on expanding its clinical evidence and achieving reimbursement for its tests is expected to drive future revenue. Personalis anticipates achieving reimbursement for at least two indications in 2025, which could enhance its financial performance. The company is strategically partnering with Tempus for sales and marketing to bolster its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.